Whole-exome sequencing identifies prognostic mutational signatures in gastric cancer

Zhenxin Zhu,Hongbing Fu,Shengzhou Wang,Xinxin Yu,Qing You,Mengyao Shi,Chun Dai,Guan Wang,Wei Cha,Weimin Wang
DOI: https://doi.org/10.21037/atm-20-6620
IF: 3.616
2020-11-01
Annals of Translational Medicine
Abstract:BACKGROUND: Gastric cancer (GC) is a heterogeneous disease, and is a leading cause of cancer deaths in Eastern Asia. Genomic analysis, such as whole-exome sequencing (WES), can help identify key genetic alterations leading to the malignancy and diversity of GC, and may help identify new drug targets.METHODS: We identified genomic alterations in a cohort of 38 GC patients, including 26 metastatic and 12 non-metastatic patients. We analyzed the association between novel gene mutations and copy number variations (CNVs) with tumor metastasis and patient survival.RESULTS: A number of significantly mutated genes in somatic and germline cells were identified. Among them, <i>ATAD3B</i> somatic mutation, a potential biomarker of immunotherapy in stomach cancers, was associated with better patient survival (P=0.0939) and metastasis (P=0.074). <i>POLE</i> germline variation was correlated with shorter overall survival (OS; P=0.0100). Novel CNVs were also identified and can potentially be used as biomarkers. These included 9p24.1 deletion (P=0.0376) and 16p11.2 amplification (P=0.0066), which were both associated with shorter OS. CNVs of several genes including <i>MMP9</i>, <i>PTPN1</i>, and <i>SS18L1</i> were found to be significantly related to metastasis (P&lt;0.05).CONCLUSIONS: We characterized the mutational landscape of 38 GC patients and discovered several potential new predictive markers of survival and metastasis in GC.
oncology,medicine, research & experimental
What problem does this paper attempt to address?